A dearth of OH/IR stars in the Small Magellanic Cloud

We present the results of targeted observations and a survey of 1612-, 1665-, and 1667-MHz circumstellar OH maser emission from asymptotic giant branch (AGB) stars and red supergiants (RSGs) in the Small Magellanic Cloud (SMC), using the Parkes and Australia Telescope Compact Array radio telescopes. No clear OH maser emission has been detected in any of our observations targeting luminous, long-period, large-amplitude variable stars, which have been confirmed spectroscopically and photometrically to be mid- to late-M spectral type. These observations have probed 3 - 4 times deeper than any OH maser survey in the SMC. Using a bootstrapping method with LMC and Galactic OH/IR star samples and our SMC observation upper limits, we have calculated the likelihood of not detecting maser emission in any of the two sources considered to be the top maser candidates to be less than 0.05%, assuming a similar pumping mechanism as the LMC and Galactic OH/IR sources. We have performed a population comparison of the Magellanic Clouds and used Spitzer IRAC and MIPS photometry to confirm that we have observed all high luminosity SMC sources that are expected to exhibit maser emission. We suspect that, compared to the OH/IR stars in the Galaxy and LMC, the reduction in metallicity may curtail the dusty wind phase at the end of the evolution of the most massive cool stars. We also suspect that the conditions in the circumstellar envelope change beyond a simple scaling of abundances and wind speed with metallicity

Developing State and National Evaluation Infrastructures- Guidance for the Challenges and Opportunities of EM&V

Evaluating the impacts and effectiveness of energy efficiency programs is likely to become increasingly important for state policymakers and program administrators given legislative mandates and regulatory goals and increasing reliance on energy efficiency as a resource. In this paper, we summarize three activities that the authors have conducted that highlight the expanded role of evaluation, measurement and verification (EM&V): a study that identified and analyzed challenges in improving and scaling up EM&V activities; a scoping study that identified issues involved in developing a national efficiency EM&V standard; and lessons learned from providing technical assistance on EM&V issues to states that are ramping up energy efficiency programs. The lessons learned are summarized in 13 EM&V issues that policy makers should address in each jurisdiction and which are listed and briefly described. The paper also discusses how improving the effectiveness and reliability of EM&V will require additional capacity building, better access to existing EM&V resources, new methods to address emerging issues and technologies, and perhaps foundational documents and approaches to improving the credibility and cross jurisdictional comparability of efficiency investments. Two of the potential foundational documents discussed are a national EM&V standard or resource guide and regional deemed savings and algorithm databases

Human Glia Can Both Induce and Rescue Aspects of Disease Phenotype in Huntington Disease

The causal contribution of glial pathology to Huntington disease (HD) has not been heavily explored. To define the contribution of glia to HD, we established human HD glial chimeras by neonatally engrafting immunodeficient mice with mutant huntingtin (mHTT)-expressing human glial progenitor cells (hGPCs), derived from either human embryonic stem cells or mHTT-transduced fetal hGPCs. Here we show that mHTT glia can impart disease phenotype to normal mice, since mice engrafted intrastriatally with mHTT hGPCs exhibit worse motor performance than controls, and striatal neurons in mHTT glial chimeras are hyperexcitable. Conversely, normal glia can ameliorate disease phenotype in transgenic HD mice, as striatal transplantation of normal glia rescues aspects of electrophysiological and behavioural phenotype, restores interstitial potassium homeostasis, slows disease progression and extends survival in R6/2 HD mice. These observations suggest a causal role for glia in HD, and further suggest a cell-based strategy for disease amelioration in this disorder

Bioactivation of Trimethoprim to Protein-Reactive Metabolites in Human Liver Microsomes

The formation of drug-protein adducts via metabolic activation and covalent binding may stimulate an immune response or may result in direct cell toxicity. Protein covalent binding is a potentially pivotal step in the development of idiosyncratic adverse drug reactions (IADRs). Trimethoprim (TMP)-sulfamethoxazole (SMX) is a combination antibiotic that commonly causes IADRs. Recent data suggest that the contribution of the TMP component of TMP-SMX to IADRs may be underappreciated. We previously demonstrated that TMP is bioactivated to chemically reactive intermediates that can be trapped in vitro by N-acetyl cysteine (NAC), and we have detected TMP-NAC adducts (i.e., mercapturic acids) in the urine of patients taking TMP-SMX. However, the occurrence and extent of TMP covalent binding to proteins was unknown. To determine the ability of TMP to form protein adducts, we incubated [14C]TMP with human liver microsomes in the presence and absence of NADPH. We observed protein covalent binding that was NADPH dependent and increased with incubation time and concentration of both protein and TMP. The estimated covalent binding was 0.8 nmol Eq TMP/mg protein, which is comparable to the level of covalent binding for several other drugs that have been associated with covalent binding–induced toxicity and/or IADRs. NAC and selective inhibitors of CYP2B6 and CYP3A4 significantly reduced TMP covalent binding. These results demonstrate for the first time that TMP bioactivation can lead directly to protein adduct formation, suggesting that TMP has been overlooked as a potential contributor of TMP-SMX IADRs

Human Glial Progenitor Cells Effectively Remyelinate the Demyelinated Adult Brain

Neonatally transplanted human glial progenitor cells (hGPCs) can myelinate the brains of myelin-deficient shiverer mice, rescuing their phenotype and survival. Yet, it has been unclear whether implanted hGPCs are similarly able to remyelinate the diffusely demyelinated adult CNS. We, therefore, ask if hGPCs could remyelinate both congenitally hypomyelinated adult shiverers and normal adult mice after cuprizone demyelination. In adult shiverers, hGPCs broadly disperse and differentiate as myelinating oligodendrocytes after subcortical injection, improving both host callosal conduction and ambulation. Implanted hGPCs similarly remyelinate denuded axons after cuprizone demyelination, whether delivered before or after demyelination. RNA sequencing (RNA-seq) of hGPCs back from cuprizone-demyelinated brains reveals their transcriptional activation of oligodendrocyte differentiation programs, while distinguishing them from hGPCs not previously exposed to demyelination. These data indicate the ability of transplanted hGPCs to disperse throughout the adult CNS, to broadly myelinate regions of dysmyelination, and also to be recruited as myelinogenic oligodendrocytes later in life, upon demyelination-associated demand

The Challenges of First-in-Human Stem Cell Clinical Trials: What Does This Mean for Ethics and Institutional Review Boards?

Stem cell-based clinical interventions are increasingly advancing through preclinical testing and approaching clinical trials. The complexity and diversity of these approaches, and the confusion created by unproven and untested stem cell-based "therapies," create a growing need for a more comprehensive review of these early-stage human trials to ensure they place the patients at minimal risk of adverse events but are also based on solid evidence of preclinical efficacy with a clear scientific rationale for that effect. To address this issue and supplement the independent review process, especially that of the ethics and institutional review boards who may not be experts in stem cell biology, the International Society for Stem Cell Research (ISSCR) has developed a set of practical questions to cover the major issues for which clear evidence-based answers need to be obtained before approving a stem cell-based trial

Freezing of the quantum Hall liquid at ν=\nu = 1/7 and 1/9

We compare the free energy computed from the ground state energy and low-lying excitations of the 2-D Wigner solid and the fractional quantum Hall liquid, at magnetic filling factors $\nu = 1/7$ and 1/9. We find that the Wigner solid melts into the fractional quantum Hall liquid at roughly the same temperature as that of some recent luminescence experiments, while it remains a solid at the lower temperatures characteristic of the transport experiments. We propose this melting as a consistent interpretation of both sets of experiments.Comment: uses RevTeX 2.0 or 3.